Clinical Spectrum of PRKAG2 Syndrome

PRKAG2 syndrome (PS) is a rare, early-onset autosomal dominant inherited disease, characterized by ventricular pre-excitation, supraventricular arrhythmias, and cardiac hypertrophy. It is frequently accompanied by chronotropic incompetence and advanced heart blocks, leading to premature pacemaker implantation. The association of these clinical features had previously been recognized by several studies since the second half of the 20th century.1–3 In 1991, PRKAG2 syndrome was mapped to the locus 7q 36,4 and in 2001, Gollob et al5 identified the responsible gene. The syndrome is caused by mutations in the gene encoding for the 5′ AMP-activated protein kinase (AMPK), specifically for its γ2 regulatory subunit (PRKAG2). AMPK is an enzyme deeply involved in cellular ATP metabolic regulation.6 PRKAG2 genetic mutations are rare and have been recognized mainly in the context of patients with nonsarcomeric familial hypertrophic cardiomyopathy associated with Wolff–Parkinson–White syndrome.7 PS can show different expressivity both of ventricular hypertrophy and arrhythmic features, ranging from an asymptomatic condition to sudden cardiac death (SCD). PS can occasionally lead to heart failure (HF) or demonstrate systemic involvement.7–9 This review aims to describe the various features and clinical implications of PS, providing clinicians and researchers with a summary of the published literature to improve the diagnosis and to better manage the clinical course of the disease. A search of the English literature was performed using PubMed up to September 2014 on the clinical features, genetics, and pathophysiology of PS syndrome. The term PRKAG2 combined with either cardiomyopathy, Wolff–Parkinson–White syndrome, atrial fibrillation, familial, left ventricular hypertrophy, atrioventricular (AV) block, pacemaker, SCD, HF, clinical characteristics, genotype, phenotype, or mutations was used. Observational studies, case reports, and reviews were included in our search. References were carefully evaluated for …

[1]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[2]  Jason Xu,et al.  Mutation in the &ggr;2-Subunit of AMP-Activated Protein Kinase Stimulates Cardiomyocyte Proliferation and Hypertrophy Independent of Glycogen Storage , 2014, Circulation research.

[3]  Hong Wu,et al.  Identification and functional analysis of a novel PRKAG2 mutation responsible for Chinese PRKAG2 cardiac syndrome reveal an important role of non-CBS domains in regulating the AMPK pathway. , 2013, Journal of cardiology.

[4]  L. Mestroni,et al.  Cardiac hypertrophy, accessory pathway, and conduction system disease in an adolescent: the PRKAG2 cardiac syndrome. , 2013, Journal of the American College of Cardiology.

[5]  C. Antzelevitch,et al.  Identification of a Novel De Novo Mutation Associated with PRKAG2 Cardiac Syndrome and Early Onset of Heart Failure , 2013, PloS one.

[6]  L. Young,et al.  AMP-Activated Protein Kinase Regulation and Biological Actions in the Heart , 2012, Circulation research.

[7]  H. Watkins,et al.  AMP-Activated Protein Kinase Phosphorylates Cardiac Troponin I and Alters Contractility of Murine Ventricular Myocytes , 2012, Circulation research.

[8]  Bingren Gao,et al.  High risk of sudden death associated with a PRKAG2-related familial Wolff-Parkinson-White syndrome. , 2011, Journal of electrocardiology.

[9]  Matthew R. G. Taylor,et al.  Natural history of Danon disease , 2011, Genetics in Medicine.

[10]  C. Wanner,et al.  The Fabry cardiomyopathy: models for the cardiologist. , 2011, Annual review of medicine.

[11]  R. Brugada,et al.  Clinical, electrocardiographic, and electrophysiologic characteristics of patients with a fasciculoventricular pathway: the role of PRKAG2 mutation. , 2011, Heart rhythm.

[12]  E. Behr,et al.  A Rare Connection: Fasciculoventricular Pathway in PRKAG2 Disease , 2010, Journal of cardiovascular electrophysiology.

[13]  Y. Hirata,et al.  The role of AMP-activated protein kinase in the cardiovascular system , 2006, Hypertension Research.

[14]  S. Thorn,et al.  In Vivo Assessment of Myocardial Glucose Uptake by Positron Emission Tomography in Adults With the PRKAG2 Cardiac Syndrome , 2009, Circulation. Cardiovascular imaging.

[15]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[16]  M. Komajda,et al.  A familial form of conduction defect related to a mutation in the PRKAG2 gene. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  A. Bonen,et al.  AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. , 2007, Biochemical and biophysical research communications.

[18]  B. Brembilla-Perrot,et al.  Supraventricular tachyarrhythmia as a cause of sudden cardiac arrest , 2006, Journal of Interventional Cardiac Electrophysiology.

[19]  Y. Başaran,et al.  Ventricular pre‐excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation , 2006, European journal of heart failure.

[20]  J. Brugada,et al.  Familial Pseudo‐Wolff‐Parkinson‐White Syndrome , 2006, Cardiovascular Electrophysiology.

[21]  N. Romero,et al.  A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis , 2006, Neuromuscular Disorders.

[22]  Ferhaan Ahmad,et al.  Increased &agr;2 Subunit–Associated AMPK Activity and PRKAG2 Cardiomyopathy , 2005, Circulation.

[23]  B. Burwinkel,et al.  Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. , 2005, American Journal of Human Genetics.

[24]  P. Elliott,et al.  Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. , 2005, Journal of the American College of Cardiology.

[25]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[26]  G. Taffet,et al.  Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome , 2005, Circulation.

[27]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[28]  J. Seidman,et al.  Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. , 2003, Journal of the American College of Cardiology.

[29]  Ferhaan Ahmad,et al.  Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy , 2003, Circulation.

[30]  M. Gollob.  Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. , 2001, Biochemical Society transactions.

[31]  M. Gollob.  Glycogen storage disease as a unifying mechanism of disease in the PRKAG 2 cardiac syndrome , 2003 .

[32]  M. Gollob,et al.  PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy , 2002, Current opinion in cardiology.

[33]  J. Seidman,et al.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. , 2002, The Journal of clinical investigation.

[34]  Y. Hellsten,et al.  Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. , 2002, Diabetes.

[35]  J. Seger,et al.  Novel PRKAG2 Mutation Responsible for the Genetic Syndrome of Ventricular Preexcitation and Conduction System Disease With Childhood Onset and Absence of Cardiac Hypertrophy , 2001, Circulation.

[36]  L. Fananapazir,et al.  Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. , 2001, The New England journal of medicine.

[37]  L. Fananapazir,et al.  Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. , 2001, The New England journal of medicine.

[38]  H. Watkins,et al.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. , 2001, Human molecular genetics.

[39]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[40]  D. Carling,et al.  Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. , 2000, The Biochemical journal.

[41]  J. Seidman,et al.  Electrophysiologic Characteristics of Accessory Atrioventricular Connections in an Inherited Form of Wolff‐Parkinson‐White Syndrome , 1999, Journal of cardiovascular electrophysiology.

[42]  D. Hardie,et al.  The AMP-activated protein kinase--fuel gauge of the mammalian cell? , 1997, European journal of biochemistry.

[43]  S. Donnelly,et al.  Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. , 1994, The Journal of clinical investigation.

[44]  J. Soni,et al.  Syncope in hypertrophic cardiomyopathy. II. Coexistence of atrioventricular block and Wolff-Parkinson-White syndrome. , 1985, American heart journal.

[45]  M. Davies,et al.  Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. , 1980, British heart journal.

[46]  S. Gulotta,et al.  Familial occurrence of sinus bradycardia, short PR interval, intraventricular conduction defects, recurrent supraventricular tachycardia, and cardiomegaly. , 1977, American heart journal.

[47]  R. Langendorf,et al.  Anatomic Findings in a Case of Ventricular Pre‐Excitation (WPW) Terminating in Complete Atrioventricular Block , 1966, Circulation.